secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001493152-24-020362
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics to host Neurotrauma Medicine webinar; will present ONP-002 mTBI update
--------------------------------------------------------------------------------

- Webinar scheduled for May 20, 2024, at 12:00 PM ET.
- Lead drug candidate ONP-002, a neurosteroid for mild TBI, to be discussed.
- Company to review preclinical/Phase I data and provide details on upcoming Phase II trial in acute/emergency settings.
- No financial results or regulatory milestones announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224020362/0001493152-24-020362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224020362/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer